Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Syndax Pharmaceuticals)"
Count: 49
Selected: 0
NCT06226571A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06132256Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT05918913Expanded Access Program for Revumenib
NCT05731947Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
NCT05406817Study of Radiolabeled Revumenib in Adults With Acute Leukemia
NCT05326516A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
NCT04710576A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT04415073A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
NCT04065399A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT03604692A Phase 1/2 Study to Evaluate SNDX- 6352 in Participants With Active cGVHD
NCT03238027A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
NCT03192111A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
NCT03187015A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects
NCT02922946Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat
NCT02922933A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects
NCT02915523Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
NCT02909452Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT02897778Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
NCT02820961Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
NCT02708680Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
NCT02437136Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer
NCT02115594Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
NCT01594398Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
NCT00866333A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
NCT00828854Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
NCT00754312A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
NCT00750698A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
NCT00676663Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
NCT00602030Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
NCT03760614A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AML
NCT06229912A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
NCT06177067Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT03765229An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
NCT03473639A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
NCT01234532Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
NCT04301778Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
NCT03361800Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
NCT05360160A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
NCT03978624Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
NCT03924245Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
NCT03179930Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
NCT03024437Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
NCT02697630Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
NCT06284486A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
NCT03250273A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
NCT03552380Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
NCT03501381High Dose IL 2 and Entinostat in RCC
NCT01928576Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.